For the second quarter of the fiscal year ending March 2027, net sales were 32,395 million yen, an increase of 3.7% year-over-year. Operating income was 1,743 million yen, up 39.7% year-over-year; ordinary income was 1,434 million yen; and net income was 1,041 million yen, all showing increases. Full-year earnings guidance was revised and the year-end dividend forecast was raised.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4538","jir_company_name":"Fuso Pharmaceutical Industries,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4538-20261111-02.pdf","jir_short_summary":"For the second quarter of the fiscal year ending March 2027, net sales were 32,395 million yen, an increase of 3.7% year-over-year. Operating income was 1,743 million yen, up 39.7% year-over-year; ordinary income was 1,434 million yen; and net income was 1,041 million yen, all showing increases. Full-year earnings guidance was revised and the year-end dividend forecast was raised.","jir_summary":"### Business Performance Overview\nFuso Pharmaceutical Industries,Ltd. reported in its interim financial summary for the fiscal year ending March 2027 that net sales were 32,395 million yen (Year-over-Year +3.7%), operating income was 1,743 million yen (Year-over-Year +39.7%), ordinary income was 1,434 million yen (Year-over-Year +26.8%), and interim net income was 1,041 million yen (Year-over-Year +25.2%). The increase in sales was attributed to deeper market penetration of core products and promotional efforts for generics; milestone revenue related to the domestic clinical trial of DMX-200 was not recognized in this period. Financially, total assets were 91,284 million yen, net assets were 36,639 million yen, and the equity ratio improved to 40.1% compared with the end of the previous fiscal year.\n\n### Outlook and Dividends\nThe company revised its full-year earnings forecast from the previously announced projection and also disclosed an increase in the year-end dividend forecast on the same date. Revisions to the full-year outlook and dividend policy based on interim results may affect the company's capital policy and financial stability; investors should monitor the latest full-year guidance disclosures closely.","jir_financial_highlights":"Net sales: 32,395 million yen (Year-over-Year +3.7%)\nOperating income: 1,743 million yen (Year-over-Year +40.0% (approx.))\nOrdinary income: 1,434 million yen (Year-over-Year +26.8%)\nInterim net income: 1,041 million yen (Year-over-Year +25.2%)\nInterim net income per share: 122.03 yen (\u2015)\nTotal assets: 91,284 million yen (Compared with fiscal year-end +1.1%)\nNet assets: 36,639 million yen (Compared with fiscal year-end +4.5%)\nEquity ratio: 40.1% (Compared with fiscal year-end +1.3pp)","jir_category":"","jir_hashtags":"#FusoPharmaceuticalIndustries, #Earnings, #InterimResults, #Pharmaceuticals, #FinancialResults","jir_key_figures":"Net sales: 32,395 million yen (Year-over-Year +3.7%)\nOperating income: 1,743 million yen (Year-over-Year +39.7%)\nInterim net income: 1,041 million yen (Year-over-Year +25.2%)","jir_meta_title":"Fuso Pharmaceutical Industries,Ltd. Q2 FY2027 Results | Net Sales 32.39 billion yen, Revenue and Profit Growth","jir_meta_description":"Fuso Pharmaceutical Industries,Ltd. Q2 results for FY ending March 2027: net sales 32,395 million yen, operating income 1,743 million yen, net income 1,041 million yen. The company revised full-year guidance and announced an increased year-end dividend forecast.","jir_og_title":"Fuso Pharmaceutical Industries,Ltd. Announces Q2 Results | Sales Up, Profits Solid","jir_og_description":"Fuso Pharmaceutical Industries,Ltd. Q2 results for FY ending March 2027: net sales 32,395 million yen, operating income approximately 1,743 million yen, net income approximately 1,041 million yen. Revisions to full-year guidance and dividend announced.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":57749,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149178","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n